Standout Papers

Cabozantinib in Progressive Medullary Thyroid Cancer 2013 2026 2017 2021 827
  1. Cabozantinib in Progressive Medullary Thyroid Cancer (2013)
    Rossella Elisei, Martin Schlumberger et al. Journal of Clinical Oncology

Immediate Impact

1 by Nobel laureates 9 from Science/Nature 61 standout
Sub-graph 1 of 21

Citing Papers

Renal cell carcinoma
2024 Standout
Arginine reprograms metabolism in liver cancer via RBM39
2023 Standout
2 intermediate papers

Works of Colin Hessel being referenced

Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.
2018
Cabozantinib in Progressive Medullary Thyroid Cancer
2013 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Colin Hessel 570 582 398 696 25 2.0k
Sophie Prévôt 156 448 601 831 64 3.0k
Abha G. Singh 286 234 396 643 28 2.4k
Seymour Grufferman 416 856 252 517 73 2.8k
Michael Collins 338 1390 656 311 28 2.6k
Ellen G. Feigal 370 1494 727 471 41 2.7k
Susanne M. Schmidt 456 399 469 607 30 1.9k
Khee‐Chee Soo 570 693 273 380 62 2.5k
Harold S. Ballard 257 461 209 565 44 2.6k
Peter Guest 584 459 228 257 38 1.5k
Paul J. Sinnott 242 286 348 532 24 2.5k

All Works

Loading papers...

Rankless by CCL
2026